ArticleDermatology and therapy2022

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.

Melinda J Gooderham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.